Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Ovarian Neoplasms 2 Melanoma 2 Head and Neck Neoplasms 2 Uveal Melanoma 1 Urogenital Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcopenia 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Diseases 1 Neoplasms, Glandular and Epithelial 1 Gliosarcoma 1 Glioblastoma 1 Genital Neoplasms, Female 1 Endometrial Neoplasms 1 Efficacy, Team 1 Carcinoma, Ovarian Epithelial 1 Advanced Solid Tumours 1 Advanced Solid Tumor 1 Adrenocortical Carcinoma 1

Interventions

pembrolizumab 1 Nivolumab 1 Immune Checkpoint Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Efficacy, Team × pembrolizumab × Clear all

NCT06693440 2024-11-18

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Henan Cancer Hospital

Efficacy, Team

Data powered by HemOnc (CC BY 4.0) Colophon ⚡